Regulus Therapeutics Inc (NASDAQ:RGLS) has received an average rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $1.25.
A number of brokerages recently issued reports on RGLS. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Wells Fargo & Co set a $162.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 19th. Finally, Wedbush reiterated a “hold” rating and set a $1.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, May 16th.
In other Regulus Therapeutics news, major shareholder Peter J. Barris purchased 1,136,704 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average cost of $1.08 per share, for a total transaction of $1,227,640.32. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joseph P. Hagan purchased 33,194 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average price of $1.08 per share, with a total value of $35,849.52. Following the completion of the purchase, the chief executive officer now directly owns 64,542 shares in the company, valued at $69,705.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 1,199,528 shares of company stock valued at $1,295,490 and have sold 66,979 shares valued at $85,896. Insiders own 10.70% of the company’s stock.
Shares of Regulus Therapeutics stock traded down $0.04 during trading hours on Tuesday, reaching $1.26. 57,013 shares of the stock traded hands, compared to its average volume of 151,139. The business’s 50 day moving average is $1.18. Regulus Therapeutics has a one year low of $0.80 and a one year high of $4.08.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.15) by $0.84. The business had revenue of $6.78 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 526.10%. On average, equities research analysts forecast that Regulus Therapeutics will post -2.13 EPS for the current fiscal year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Recommended Story: The risks of owning bonds
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.